China factory High Quality Pure 99% Peptide NA-931 bioglutide, Tirzepatide, semaglutide and retatrutide
13 Inquiries
123475-27-4
Pharmaceutical Grade
99%
shenzhen
DL
10mg/vial,10vials/box
2026-02-28
Tirzepatide,Retatrutide,Semaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Beinaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Beinaglutide is characterized by its peptide structure and high purity, making it suitable for API research, pharmaceutical development, analytical testing, and manufacturing processes.
Basic Info-
Product Name:
Beinaglutide
CAS No.:123475-27-4
Molecular Formula:C149H225N39O46
Categories:
Research-
Class:
GLP-1 receptor agonist (native human GLP-1(7-36) sequence, short-acting)
Status:China NMPA-approved (谊生泰 / Beinaglutide 2016) — Not FDA-approved
Mechanism:Beinaglutide is a recombinant human GLP-1(7-36) peptide with nearly 100% homology to the endogenous human GLP-1 sequence. Unlike other GLP-1R agonists, it is not modified to resist DPP-IV degradation, giving it a short half-life of ~2 minutes. It requires three-times-daily subcutaneous injection. It enhances glucose-dependent insulin secretion, inhibits gastric emptying, and reduces food intake.
Activity note:Beinaglutide is the native GLP-1(7-36) sequence; it binds GLP-1R with potency comparable to endogenous GLP-1. Specific EC50 values are not in standard drug databases; native GLP-1 EC50 is ~10 pM.
Source:MCE product data: CAS 123475-27-4; Yeasen product sheet.
Clinical Development:
References-
PubChem:Literature:
MCE: Beinaglutide (CAS 123475-27-4); PubMed: Zhang F, et al. (2016) — Beinaglutide Phase 3 (Chinese)
Disclaimer:Beinaglutide is approved by China NMPA (not FDA) as a prescription medicine for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide
-
Location:
Room 1811-A096, Jingu Building, No.319 Jinxing Middle Road, Xihu Street, Yuelu District, Changsha City, Hunan Province
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
2
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History13 Inquiries
Country Product Purchase Quantity Date Posted
Mexico
BIOGLUTIDE
1 KG Aug 4, 2025
Australia
Bioglutide
1 Dec 15, 2025
United States
bioglutide
10 MG Oct 23, 2025
Norway
Bioglutide
1 MT Sep 25, 2025
United States
NA-931 Bioglutide
50 G Apr 2, 2026
United States
bioglutide na-931
1 KG Dec 29, 2025
United States
Beinaglutide
10 MG Dec 26, 2025
Mexico
Beinaglutide
100 MT Aug 4, 2025
United Kingdom
bioglutide NA931
30 MG Jan 26, 2026
Malaysia
bioglutide
1 KG Jan 12, 2026
United Kingdom
Na931
100 PCS Dec 31, 2025
United States
NA-931
1 KG Dec 29, 2025
Belgium
Bioglutide
10 MG Nov 21, 2025 Post an enquiry for this product